News for Zoetis Inc. (ZTS)

It's always a good time to buy solid dividend stocks, but considering the challenging economic environment, now might be a particularly opportune time. With a volatile equity market and a potential recession looming due to the impact of tariffs, dividend stocks can help strengthen any portfolio. With that as a backdrop, let's consider four excellent income stocks that investors can buy amid the current sell-off: AbbVie (NYSE: ABBV), Amgen (NASDAQ: AMGN), Bristol Myers Squibb (NYSE: BMY), and Zoetis (NYSE: ZTS).

Summary: Zoetis Inc. (ZTS) is positioned for a potential 35.1% return based on the current stock price and Wall Street forecasts.Analysts' average one-year pric

Zoetis (NYSE: ZTS) is a leading animal healthcare company offering over 300 medicines, vaccines, and other precision health products to care for companion animals and livestock globally. Since its spin-off from Pfizer in 2013, Zoetis has delivered an annualized total return of 15%, demonstrating the market-beating potential of what might look like a steady-Eddie investment at first glance. Following this decline, though, Zoetis now trades at a price-to-earnings (P/E) ratio of 27 -- its lowest mark in a decade.

Stifel analyst Jonathan Block has revised his outlook for Zoetis (ZTS), reducing the price target from $180 to $165 while maintaining a Buy rating. This adjustm

Shares of Zoetis Inc (ZTS) fell 5.45% in mid-day trading on Apr 10. The stock reached an intraday low of $142.04, before recovering slightly to $145.18, dow

We recently published a list of 15 Stocks with Buy Ratings that Hedge Funds Love. In this article, we are going to take a look at where Zoetis Inc. (NYSE:ZTS) stands against other stocks with buy ratings that hedge funds love. The U.S. stock market has been in chaos ever since President Trump announced his […]

There are many dividend stocks on equity markets, but not all are attractive to income investors. Here's why this is a top dividend stock to hold on to for the next decade. Zoetis is the world's leading drugmaker focused on animal health.

The latest trading day saw Zoetis (ZTS) settling at $163.11, representing a -1.16% change from its previous close.

Shares in animal pharmaceutical company Zoetis (NYSE: ZTS) have been under a cloud since the release of the company's fourth-quarter earnings report in mid-February. The Q4 numbers were fine, but the company's revenue guidance fell short of expectations. One major alternative consideration could end up providing an upside or downside to expectations.

Zoetis operates in a growing animal healthcare market, benefiting from trends like pet humanization and medicalization. Read why ZTS stock is a Buy.

Zoetis (ZTS) closed the most recent trading day at $163.03, moving -0.08% from the previous trading session.

The latest trading day saw Zoetis (ZTS) settling at $160.06, representing a -1% change from its previous close.

Zoetis divests its MFA segment to boost margins while focusing on profitable areas like genetics. Click here to find out why ZTS stock is a Buy.

Zoetis Inc. (NYSE:ZTS) Barclays 27th Annual Global Healthcare March 11, 2025 10:30 AM ETCompany ParticipantsWetteny Joseph - Chief Financial...

Zoetis (ZTS) reachead $170.37 at the closing of the latest trading day, reflecting a +1.87% change compared to its last close.

We recently published a list of 10 Best Weight Loss Drug Stocks to Buy According to Analysts. In this article, we are going to take a look at where Zoetis Inc.

Zoetis Inc. (NYSE:ZTS) BofA Securities 2025 Animal Health Summit February 27, 2025 1:20 PM ETCompany ParticipantsWetteny Joseph - CFOConference Call...

Zoetis Inc (ZTS) has recently been in the spotlight, drawing interest from investors and financial analysts due to its robust financial stance. With shares curr

Robust product innovation and market leadership in veterinary diagnostics.Expansive global presence with a focus on enhancing veterinary practice efficiency.Ch